OBIO Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $2.42 - $6.48

6.2 Year OBIO Performance Metrics:

Total Return (with DRIP): -45.4% (-9.31% CAGR)

Total Return (no DRIP): -45.4% (-9.31% CAGR)

Share Price: -45.4% (-9.31% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $5,456

Total Return $ (with DRIP): -$4,544

OBIO Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

OBIO Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for OBIO

Based on past 6.2-year performance, here are OBIO growth metrics:

Share price CAGR of -9.31%
Dividend CAGR of +0%

Using OBIO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	OBIO (DRIP)	OBIO - No DRIP
Current Price	$6.22	$6.22
Start Shares	1,607.72	1,607.72
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,607.72	1,607.72
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$2.34	$6.22
Total Dividends	$0	$0
Final Value	$3,764	$10,000

Estimated Future Value + Dividends - OBIO

NOTE: Above numbers are our estimate based on OBIO's Dividend and Price CAGR over past 6.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Orchestra BioMed Holdings, Inc. (OBIO) had its IPO on , and is traded on NASDAQ stock exchange.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions. Its current portfolio centers on AVIM Therapy, a bioelectronic treatment candidate designed to help lower blood pressure in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon, a drug-device platform intended for treating atherosclerotic artery disease. The company also works on cardiac neuromodulation programs and minimally invasive device technologies that support interventional procedures. Orchestra BioMed’s business model relies on partnerships with established medical device companies to advance clinical development and commercialization. Headquartered in New Hope, Pennsylvania, Orchestra BioMed plays a niche role in the medical technology market by combining device innovation, bioelectronic therapy, and targeted drug delivery within cardiovascular care.

OBIO website: https://www.orchestrabiomed.com